An update on the application of physical technologies to enhance intradermal and transdermal drug delivery

Therapeutic Delivery

Volumn 3, Issue 3, 2012, Pages 339-355

  Herwadkar, Anushree ^a   Banga, Ajay K ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON NANOTUBE; CEFAZOLIN; COSMETIC; ECONAZOLE; FENTANYL; GRANISETRON; HEPATITIS B VACCINE; HUMAN GROWTH HORMONE; HYALURONIC ACID; IBUPROFEN; INFLUENZA VACCINE; INSULIN; LEVODOPA; LIDOCAINE; METHYLPHENIDATE; MORPHINE; NANOPARTICLE; NP 101; PANTOTHENIC ACID; PARATHYROID HORMONE; PLACEBO; SOLID LIPID NANOPARTICLE; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; VACCINE;

AEROSOL; BLOOD LEVEL; CHRONIC PAIN; CLINICAL EFFECTIVENESS; DEVICE SAFETY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; EQUIPMENT DESIGN; HUMAN; HYDROPHILICITY; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; LIPOPHILICITY; LIPOSOMAL DELIVERY; MACROMOLECULE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MICROINJECTION; MICROINJECTOR; MICROIONTOPHORESIS; MIGRAINE; NANOPHARMACEUTICS; NEEDLE; NONHUMAN; PAIN; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; POROSITY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN PERMEABILITY; STAPHYLOCOCCUS INFECTION; SUSTAINED DRUG RELEASE; SYSTEMIC DISEASE; TABLET; TRANSDERMAL PATCH; ULTRASOUND; VACCINATION;

EID: 84858131030     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.1     Document Type: Review

References (96)

1. Banga AK. Transdermal and Intradermal Delivery of Therapeutic Agents: Application of Physical Technologies. CRC Press, Boca Raton, FL, USA (2011).
2. Escobar-Chavez JJ, Bonilla-Martinez D, Villegas-Gonzalez MA, Molina-Trinidad E, Casas-Alancaster N, Revilla-Vazquez AL. Microneedles: a valuable physical enhancer to increase transdermal drug delivery. J. Clin. Pharmacol. 51(7), 964-977 (2011).
3. Banga AK. Microporation applications for enhancing drug delivery. Expert Opin. Drug Deliv. 6(4), 343-354 (2009).
4. Sachdeva V, Banga AK. Iontophoresis: promises and challenges. Transdermal 2(1), 17-21(2010).
5. Mitragotri S, Kost J. Low-frequency sonophoresis: a review. Adv. Drug Deliv. Rev. 56(5), 589-601 (2004). (Pubitemid 38326935)
6. Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J. Control. Release 152(3), 330-348 (2011).
7. Mathur V, Satrawala Y. Rajput MS. Physical and chemical penetration enhancers in transdermal drug delivery system. Asian J. Pharmaceutics 4(3), 173-183 (2010).
8. Valecha VMP, Syan N, Verma S. Various penetration enhancement techniques in transdermal drug delivery. Int. J. Pharm. Technol. 3(2), 2373-2401 (2011).
9. Amorij JP, Hinrichs W, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect. Dis. 10, 699-711 (2010).
10. Leroux-Roels I, Vets E, Freese R et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine 26(51), 6614-6619 (2008).
11. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26(26), 3197-3208 (2008).
12. Laurent A, Mistretta F, Bottigioli D et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 25(34), 6423-6430 (2007). (Pubitemid 47096751)
13. Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25(52), 8833-8842 (2007). (Pubitemid 350192056)
14. Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650-658 (2008).
15. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: randomized, controlled, Phase III trial. Hum. Vaccines 6(4), 346-354).
16. Arnou R, Icardi G, De Decker M et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter Phase III study. Vaccine 27(52), 7304-7312 (2009).
17. Beran J, Ambrozaitis A, Laiskonis A et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 7, 13 (2009).
18. Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351(22), 2286-2294 (2004). (Pubitemid 39552744)
19. Falsey AR. New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine 28(Suppl. 4), D24-D32 (2010).
20. Milewski M, Brogden NK, Stinchcomb AL. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opin. Drug Deliv. 7(5), 617-629 (2010).
21. Kalluri H, Banga AK. Formation and closure of microchannels in skin following microporation. Pharm. Res. 28(1), 82-94 (2011).
22. Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J. Control. Release 154(2), 148-155 (2011).
23. Haq MI, Smith E, John DN et al. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed. Microdevices 11(1), 35-47 (2009).
24. Banks SL, Pinninti RR, Gill HS et al. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J. Pharm. Sci. 99(7), 3072-3080 (2010).
25. Wermeling DP, Banks SL, Hudson DA et al. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc. Natl Acad. Sci. USA 105(6), 2058-2063 (2008). (Pubitemid 351439464)
26. Banks SL, Paudel KS, Stinchcomb AL, Loftin CD. COX enzyme inhibitor enables drug delivery through microneedle treated skin for seven days. AllTranz Inc., University of Kentucky. Conference Report. AAPS Annual Meeting and Exposition, Atlanta GA, USA Abstract Number: T3023 (2008).
27. Donnelly RF, Singh TR, Tunney MM et al. Microneedle arrays allow lower microbial penetration than hypodermic needles in vitro. Pharm. Res. 26(11), 2513-2522 (2009).
28. Li WZ, Huo MR, Zhou JP et al. Super-short solid silicon microneedles for transdermal drug delivery applications. Int. J. Pharm. 389(1-2), 122-129 (2010).
29. Sintov AC, Krymberk I, Daniel D, Hannan T, Sohn Z, Levin G. Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. J. Control. Release 89(2), 311-320 (2003). (Pubitemid 36507024)
30. Birchall J, Coulman S, Anstey A et al. Cutaneous gene expression of plasmid DNA in excised human skin following delivery via microchannels created by radio frequency ablation. Int. J. Pharm. 312(1-2), 15-23 (2006).
31. Levin G, Gershonowitz A, Sacks H et al. Transdermal delivery of human growth hormone through RF-microchannels. Pharm. Res. 22(4), 550-555 (2005). (Pubitemid 40603252)
32. Cazares-Delgadillo J, Ganem-Rondero A, Kalia YN. Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance. Eur. J. Pharm. Biopharm. 78(2), 278-288 (2011).
33. Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int. J. Pharm. 364(2), 227-236 (2008).
34. Power I. Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain. Br. J. Anaesthesia 98(1), 4-11 (2007). (Pubitemid 44896744)
35. Sinatra R. The fentanyl HCl patient-controlled transdermal system (PCTS): an alternative to intravenous patient-controlled analgesia in the postoperative setting. Clin. Pharmacokinet. 44(Suppl. 1), 1-6 (2005). (Pubitemid 41626711)
36. Mayes S, Ferrone M. Fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain. Ann. Pharmacother. 40(12), 2178-2186 (2006).
37. Sathyan G, Jaskowiak J, Evashenk M, Gupta S. Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration. Clin. Pharmacokinet. 44(Suppl. 1), 7-15 (2005). (Pubitemid 41626712)
38. Sathyan G, Zomorodi K, Gidwani S, Gupta S. The effect of dosing frequency on the pharmacokinetics of a fentanyl HCl patient-controlled transdermal system (PCTS). Clin. Pharmacokinet. 44(Suppl. 1), 17-24 (2005). (Pubitemid 41626713)
39. Gupta SK, Hwang S, Southam M, Sathyan G. Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). Clin. Pharmacokinet. 44(Suppl. 1), 25-32 (2005). (Pubitemid 41626714)
40. Chelly JE, Grass J, Houseman TW, Minkowitz H, Pue A. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial. Anesth. Analg. 98(2), 427-433 (2004). (Pubitemid 38129392)
41. Viscusi ER, Reynolds L, Tait S, Melson T, Atkinson LE. An iontophoretic fentanyl patient-activated analgesic delivery system for postoperative pain: a double-blind, placebo-controlled trial. Anesth. Analg. 102(1), 188-194 (2006). (Pubitemid 43038306)
42. Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA 291(11), 1333-1341 (2004). (Pubitemid 38541648)
43. Poon K-Hea. Efficacy of fentanyl iontophoretic transdermal system in postoperative pain-a meta-analysis. Acute Pain 11, 65-74 (2009).
44. Dubin CH. Transdermal delivery becoming more active. Drug Delivery Technology 8(7), 38-43 (2008).
45. Durand EA. Intelligent sustained-release using a selective charged barrier membrane. Drug Delivery Technology 9(5), 28-31 (2009).
46. Rapoport A. New frontiers in headache therapy. Neurol. Sci. 32(Suppl. 1), S105-S109 (2011).
47. Rapoport AM. New acute treatments for headache. Neurol. Sci. 31(Suppl. 1), S129-S132 (2010).
48. Pierce M, Marbury T, O'Neill C, Siegel SJ, Du W, Sebree T. NP101: a novel formulation of sumatriptan succinate using SmartreliefTM transdermal technology. Presented at: The 50th Annual Scientific Meeting of the American Headache Society, Boston, MA, USA, 28 June 2008.
49. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T. Zelrix: a novel transdermal formulation of sumatriptan. Headache 49(6), 817-825 (2009).
50. Siegel SJ, O'Neill C, Dube LM et al. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm. Res. 24(10), 1919-1926 (2007). (Pubitemid 47389248)
51. Charoo NA, Rahman Z, Repka MA, Murthy SN. Electroporation: an avenue for transdermal drug delivery. Curr. Drug Deliv. 7(2), 125-136 (2010).
52. Denet AR, Vanbever R, Preat V. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev. 56(5), 659-674 (2004). (Pubitemid 38326938)
53. Gomez C, Costela A, Garcia-Moreno I, Llanes F, Teijon JM, Blanco D. Laser treatments on skin enhancing and controlling transdermal delivery of 5-fluorouracil. Lasers Surg. Med. 40(1), 6-12 (2008). (Pubitemid 351214118)
54. Yu J, Kalaria DR, Kalia YN. Erbium: YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies. J. Control. Release 156(1), 53-59 (2011).
55. Doukas AG, Kollias N. Transdermal drug delivery with a pressure wave. Adv. Drug Deliv. Rev. 56(5), 559-579 (2004). (Pubitemid 38326933)
56. Menon GK, Kollias N, Doukas AG. Ultrastructural evidence of stratum corneum permeabilization induced by photomechanical waves. J. Invest. Dermatol. 121(1), 104-109 (2003). (Pubitemid 36900461)
57. Murthy SN, Sammeta SM, Bowers C. Magnetophoresis for enhancing transdermal drug delivery: mechanistic studies and patch design. J. Control. Release 148(2), 197-203 (2010).
58. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 13(3), 175-187 (2006).
59. Andrews S, Lee JW, Choi SO, Prausnitz MR. Transdermal insulin delivery using microdermabrasion. Pharm. Res. 28(9), 2110-2118 (2011).
60. Neubert RHH. Potentials of new nanocarriers for dermal and transdermal delivery. Eur. J. Pharm. Biopharm. 77, 1-2 (2011).
61. Schroeter A, Engelbrecht T, Neubert RH, Goebel AS. New nanosized technologies for dermal and transdermal drug delivery. A review. J. Biomed. Nanotechnol. 6(5), 511-528 (2010).
62. Tolia GT, Choi HH. The role of dendrimers in topical drug delivery. Pharmaceutical Technol. 32(11), 88-98 (2008).
63. Im JS, Bai B, Lee YS. The effect of carbon nanotubes on drug delivery in an electro-sensitive transdermal drug delivery system. Biomaterials 31(6), 1414-1419 (2010).
64. Pierre MB, Dos Santos Miranda Costa I. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch. Dermatol. Res. 303(9), 607-621 (2011).
65. El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur. J. Pharm. Sci. 34(4-5), 203-222 (2008).
66. Naeff R. Feasibility of topical liposome drugs produced on an industrial scale. Adv. Drug Deliv. Rev. 18(3), 343-347 (1996).
67. Sand M, Bechara FG, Sand D, Altmeyer P, Hoffmann K. A randomized, controlled, double-blind study evaluating melanin-encapsulated liposomes as a chromophore for laser hair removal of blond, white, and gray hair. Ann. Plast. Surg. 58(5), 551-554 (2007). (Pubitemid 46659148)
68. Verma P, Pathak K. Nanosized ethanolic vesicles loaded with econazole nitrate for the treatment of deep fungal infections through topical gel formulation. Nanomedicine (2011) (Epub ahead of print).
69. Bahia AP, Azevedo EG, Ferreira LA, Frezard F. New insights into the mode of action of ultradeformable vesicles using calcein as hydrophilic fluorescent marker. Eur. J. Pharm. Sci. 39(1-3), 90-96 (2010).
70. Gillet A, Lecomte F, Hubert P, Ducat E, Evrard B, Piel G. Skin penetration behaviour of liposomes as a function of their composition. Eur. J. Pharm. Biopharm. 79(1), 43-53 (2011).
71. Bjorklund S, Engblom J, Thuresson K, Sparr E. A water gradient can be used to regulate drug transport across skin. J. Control. Release 143(2), 191-200 (2010).
72. Honeywell-Nguyen PL, Wouter Groenink HW, de Graaff AM, Bouwstra JA. The in vivo transport of elastic vesicles into human skin: effects of occlusion, volume and duration of application. J. Control. Release 90(2), 243-255 (2003). (Pubitemid 36694967)
73. Manosroi A, Khanrin P, Lohcharoenkal W et al. Transdermal absorption enhancement through rat skin of gallidermin loaded in niosomes. Int. J. Pharm. 392(1-2), 304-310 (2010).
74. Hwang BY, Jung BH, Chung SJ, Lee MH, Shim CK. In vitro skin permeation of nicotine from proliposomes. J. Control. Release 49(2-3), 177-184 (1997).
75. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv. Coll. Interface Sci. 123-126, 369-385 (2006). (Pubitemid 44665819)
76. Naoui W, Bolzinger MA, Fenet B et al. Microemulsion microstructure influences the skin delivery of an hydrophilic drug. Pharm. Res. 28(7), 1683-1695 (2011).
77. Lee PJ, Langer R, Shastri VP. Novel microemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs. Pharm. Res. 20(2), 264-269 (2003). (Pubitemid 36269734)
78. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54(Suppl. 1), S131-S155 (2002). (Pubitemid 35379959)
79. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 58(1), 68-89 (2006).
80. Paccalin Mea. The intradermal vaccination route-an attractive opportunity for influenza vaccination in the elderly. Eur. Geriatric Med. 1, 82-87 (2010).
81. Matsuo K, Ishii Y, Quan YS et al. Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat. J. Control. Release 149(1), 15-20 (2011).
82. Ishii Y, Nakae T, Sakamoto F et al. A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. J. Control. Release 131(2), 113-120 (2008).
83. Hickey DK, Aldwell FE, Tan ZY, Bao S, Beagley KW. Transcutaneous immunization with novel lipid-based adjuvants induces protection against gastric Helicobacter pylori infection. Vaccine 27(50), 6983-6990 (2009).
84. Ansaldi F, Durando P, Icardi G. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin. Biol. Ther. 11(3), 415-427 (2011).
85. Kim YC, Prausnitz MR. Enabling skin vaccination using new delivery technologies. Drug Deliv. Transl. Res. 1(1), 7-12 (2011).
86. Laurent PE, Bourhy H, Fantino M, Alchas P, Mikszta JA. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 28(36), 5850-5856 (2010).
87. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369-393 (2009).
88. Widera G, Johnson J, Kim L et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 24(10), 1653-1664 (2006). (Pubitemid 43238242)
89. Zhu Q, Zarnitsyn VG, Ye L et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl Acad. Sci. USA 106(19), 7968-7973 (2009).
90. Ding Z, Van Riet E, Romeijn S, Kersten GF, Jiskoot W, Bouwstra JA. Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharm. Res. 26(7), 1635-1643 (2009).
91. Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J. Control. Release 147(3), 326-332 (2010).
92. Hirschberg HJ, van de Wijdeven GG, Kraan H, Amorij JP, Kersten GF. Bioneedles as alternative delivery system for hepatitis B vaccine. J. Control. Release 147(2), 211-217 (2010).
93. Baxter J, Mitragotri S. Jet-induced skin puncture and its impact on needle-free jet injections: experimental studies and a predictive model. J. Control. Release 106(3), 361-373 (2005). (Pubitemid 41187445)
94. Dean HJ, Fuller D, Osorio JE. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp. Immunol. Microbiol. Infect. Dis. 26(5-6), 373-388 (2003). (Pubitemid 37168474)
95. Tezel A, Paliwal S, Shen Z, Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23(29), 3800-3807 (2005). (Pubitemid 40704743)
96. Dahlan A, Alpar HO, Stickings P, Sesardic D, Murdan S. Transcutaneous immunisation assisted by low-frequency ultrasound. Int. J. Pharm. 368(1-2), 123-128 (2009).